Andrew H. Galligan Net Worth

The estimated Net Worth of Andrew H Galligan is at least $4.47 Million dollars as of 28 February 2020. Mr Galligan owns over 8,000 units of Nevro Corp stock worth over $289,618 and over the last 10 years he sold NVRO stock worth over $3,404,050. In addition, he makes $776,951 as Exec. Officer at Nevro Corp.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr Galligan NVRO stock SEC Form 4 insiders trading

Mr has made over 27 trades of the Nevro Corp stock since 2015, according to the Form 4 filled with the SEC. Most recently he exercised 8,000 units of NVRO stock worth $28,800 on 28 February 2020.

The largest trade he's ever made was exercising 134,100 units of Nevro Corp stock on 8 July 2019 worth over $120,690. On average, Mr trades about 9,533 units every 34 days since 2014. As of 28 February 2020 he still owns at least 61,490 units of Nevro Corp stock.

You can see the complete history of Mr Galligan stock trades at the bottom of the page.

Mr. Andrew H. Galligan biography

Andrew H. Galligan is the Exec. Officer at Nevro Corp.

What is the salary of Mr Galligan?

As the Exec. Officer of Nevro Corp, the total compensation of Mr Galligan at Nevro Corp is $776,951. There are 7 executives at Nevro Corp getting paid more, with D.Keith Grossman having the highest compensation of $13,877,700.

How old is Mr Galligan?

Mr Galligan is 65, he's been the Exec. Officer of Nevro Corp since . There are 2 older and 22 younger executives at Nevro Corp. The oldest executive at Nevro Corp is Frank Fischer, 78, who is the Independent Director.

What's Mr Galligan's mailing address?

Andrew's mailing address filed with the SEC is C/O OOMA, INC., 525 ALMANOR AVE., SUITE 200, SUNNYVALE, CA, 94085.

Insiders trading at Nevro Corp

Over the last 10 years, insiders at Nevro Corp have traded over $298,472,982 worth of Nevro Corp stock and bought 312,708 units worth $8,709,518 . The most active insiders traders include Ali Behbahani, Holdings A/S Novo und & Johnson Johnson & Johnson.... On average, Nevro Corp executives and independent directors trade stock every 18 days with the average trade being worth of $161,002. The most recent stock trade was executed by Shawn Mc Cormick on 7 June 2023, trading 7,500 units of NVRO stock currently worth $171,600.

What does Nevro Corp do?

headquartered in redwood city, california, nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. nevro has developed and commercialized the senza spinal cord stimulation (scs) system, an evidence-based neuromodulation platform for the treatment of chronic pain. the senza system is the only scs system that delivers nevro's proprietary hf10 therapy. the nevro® senza® scs system received ce mark in 2010, tga approval in 2011, fda approval in 2015, and is commercially available in europe, australia, and the united states.

Complete history of Mr Galligan stock trades at Nevro Corp und Ooma Inc

Nevro Corp executives and stock owners

Nevro Corp executives and other stock owners filed with the SEC include:

• D.Keith Grossman,
  Chairman of the Board, President, Chief Executive Officer
• Niamh Pellegrini,
  Chief Commercial Officer
• Michael Carter,
  Vice President - Global Sales
• Christopher Christoforou,
  Vice President - Research and Development
• D. Keith Grossman,
  Chairman, CEO & Pres
• Patrick Schmitz,
  Vice President - Operations
• Kashif Rashid,
  Chief Compliance Officer, General Counsel, Corporate Secretary
• Andrew H. Galligan,
  Exec. Officer
• Kashif Rashid,
  Gen. Counsel, Corp. Sec. & Chief Compliance Officer
• Roderick H. MacLeod,
  Chief Financial Officer
• Elizabeth Weatherman,
  Independent Director
• Kevin O'Boyle,
  Independent Director
• Karen Prange,
  Independent Director
• Michael DeMane,
  Lead Independent Director
• Wilfred Jaeger,
  Independent Director
• Shawn McCormick,
  Independent Director
• Frank Fischer,
  Independent Director
• Brad Vale,
  Independent Director
• David Caraway,
  Chief Medical Officer
• Donald Middlebrook,
  Vice President - Clinical, Regulatory and Quality
• Juliet Cunningham,
  Vice President - Investor Relations
• Lori Ciano,
  Chief Human Resource Officer
• Roderick MacLeod,
  Chief Financial Officer
• Dr. David Caraway,
  Chief Medical Officer
• Lori M. Ciano,
  Chief HR Officer
• Patrick Schmitz,
  VP of Operations
• Jon R. Shear,
  VP of Corp. Devel.
• Michael Collier Carter,
  VP of Global Sales
• Julie D. Dewey,
  Chief Corp. Communications & Investor Relations Officer
• Sridhar Kosaraju,
  
• James Alecxih,
  Vice President, Sales
• Lisa D Earnhardt,
  Director
• Andre Walker,
  Senior VP,Research&Development
• Ali Behbahani,
  Director
• Kevin R Thornal,
  President & CEO
• Rami Elghandour,
  President
• Michael Enxing,
  VP of Sales & Marketing
• Arch Management Iv, L.L.C.T...,
  
• City Capital Llc Bay City C...,
  
• Holdings A/S Novo,
  10% owner
• Partners Ii Lp Amv,
  
• City Capital Llc Bay City C...,
  
• Nathan B Pliam,
  Director
• & Johnson Johnson & Johnson...,
  
• Balakrishnan Shankar,
  VP, Operations
• Andrew H Galligan,
  Chief Financial Officer
• Doug Alleavitch,
  VP, Quality
• Kirt P Karros,
  
• Christofer Christoforou,
  SVP, Chief Operating Officer
• Greg Siller,
  SVP & Chief Commercial Officer
• Richard B. Carter,
  Chief Accounting Officer
• Susan E Siegel,